INMB - INmune Bio

-

$undefined

N/A

(N/A)

INmune Bio NasdaqCM:INMB INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Location: 225 NE Mizner Blvd., Boca Raton, FL, 33432, United States | Website: https://www.inmunebio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

151.8M

Cash

19.34M

Avg Qtr Burn

-8.177M

Short % of Float

38.59%

Insider Ownership

28.19%

Institutional Own.

25.67%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CORDStrom Details
Recessive dystrophic epidermolysis bullosa

BLA

Submission

XPro1595 (XPro™) Details
Alzheimer's disease

Big Mover™

Susp. Mover™

Phase 2

Data readout

INKmune™ Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Big Mover™

Susp. Mover™

Phase 2

Data readout

INB03 + trastuzumab-deruxtecan Details
Cancer, Pancreatic cancer, Gastric cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer

Phase 2

Update

XPro1595 (XPro™) (pegipanermin fr) Details
Major depressive disorder, Mental health, Treatment Resistant Depression

Phase 2

Initiation

INKmune™ Details
Cancer, Myelodysplastic syndrome, Acute myeloid leukemia

Failed

Discontinued

LIVNate Details
Liver disease, NASH-induced significant or severe fibrosis

Failed

Discontinued

Failed

Discontinued